Symptomatic atherosclerosis is associated with an altered gut metagenome

Fredrik H Karlsson, Frida Fåk, Intawat Nookaew, Valentina Tremaroli, Björn Fagerberg, Dina Petranovic, Fredrik Bäckhed, Jens Nielsen, Fredrik H Karlsson, Frida Fåk, Intawat Nookaew, Valentina Tremaroli, Björn Fagerberg, Dina Petranovic, Fredrik Bäckhed, Jens Nielsen

Abstract

Recent findings have implicated the gut microbiota as a contributor of metabolic diseases through the modulation of host metabolism and inflammation. Atherosclerosis is associated with lipid accumulation and inflammation in the arterial wall, and bacteria have been suggested as a causative agent of this disease. Here we use shotgun sequencing of the gut metagenome to demonstrate that the genus Collinsella was enriched in patients with symptomatic atherosclerosis, defined as stenotic atherosclerotic plaques in the carotid artery leading to cerebrovascular events, whereas Roseburia and Eubacterium were enriched in healthy controls. Further characterization of the functional capacity of the metagenomes revealed that patient gut metagenomes were enriched in genes encoding peptidoglycan synthesis and depleted in phytoene dehydrogenase; patients also had reduced serum levels of β-carotene. Our findings suggest that the gut metagenome is associated with the inflammatory status of the host and patients with symptomatic atherosclerosis harbor characteristic changes in the gut metagenome.

Conflict of interest statement

J.N and F.B. are shareholders in MetaboGen AB. All other authors declare no competing financial interests.

Figures

Figure 1. Microbial composition associated with symptomatic…
Figure 1. Microbial composition associated with symptomatic atherosclerosis.
(a) Illustration of our bioinformatics pipeline for analysing metagenome data to elucidate its relation to human metabolic disease. Sequence reads from the gut metagenome were generated with high-throughput sequencing technology and subjected to quality control. High-quality reads were used for alignment to reference genomes to estimate species abundance. De novo assembly of the metagenome allows for discovery of new genes not yet found in databases. Annotation of genes to KEGG allows for integration of information at the gene level with the metabolic network. Data on plasma metabolites and proteins together with gut metagenomic data constitute a basis for discovery of mechanisms for gut metagenome association with etiology of complex diseases. (b) Principal component analysis of microbial species abundance using health status as instrumental variable. Red is patients (P, n=12), green controls (C, n=13). The relation between microbial abundance and health status was assessed with Monte Carlo simulations with 10,000 replications by which a P-value was calculated. (c) Abundance of bacterial genera and species that differ between patients (n=12) with symptomatic atherosclerosis (P) and controls (n=13) (C). Adj. P<0.05 for all. (d) Bacterial genera correlating with biomarkers of atherosclerosis, using Spearman’s correlation. All samples, including the two excluded controls (see methods for details), were used for correlations with triglycerides, CRP (n=27, respectively) and white blood cell count (WBC; n=23). Only controls were used for low-density lipoprotein (LDL), high-density lipoprotein (HDL) and cholesterol correlations to avoid interactions with possible drug effects (n=15). *Adj. P<0.05, **adj. P<0.01 and ***adj. P<0.001. Boxes denote the interquartile range (IQR) between the first and third quartiles and the line within denotes the median; whiskers denote the lowest and highest values within 1.5 times IQR from the first and third quartiles, respectively. Circles denote data points beyond the whiskers.
Figure 2. Symptomatic atherosclerosis correlates with gut…
Figure 2. Symptomatic atherosclerosis correlates with gut enterotypes.
(a) Three enterotypes in our cohort based on the abundance of genera. Controls and patients are denoted by filled triangles and empty triangles, respectively. Two subjects not included in the comparison are represented by empty circles. Green is enterotype 1, red is enterotype 2 and blue is enterotype 3. (b) Abundance of Bacteroides, Prevotella and Ruminococcus, proposed drivers of the three enterotypes. Boxes denote the interquartile range (IQR) between the first and third quartiles and the line within denotes the median; whiskers denote the lowest and highest values within 1.5 times IQR from the first and third quartiles, respectively. Circles denote data points beyond the whiskers.
Figure 3. KOs are associated with symptomatic…
Figure 3. KOs are associated with symptomatic atherosclerosis.
(a) Peptidoglycan KOs were enriched in patients and eight out of nine KOs correlated positively with white blood cell levels. (b) β-Oxidation KOs correlate with plasma triglyceride levels. (c) The glutamine synthetase—glutamine oxoglutarate aminotransferase system (K00265, K00266 and K01915) with high affinity for ammonium is enriched in patients. In all panels, red indicates enriched in patients (P), green indicates enriched in controls (C). *Adj. P<0.05, **adj. P<0.01 and ***adj. P<0.001. All samples were used for correlations with triglycerides, CRP (n=27, respectively) and white blood cell count (WBC; n=23). Only controls were used for low-density lipoprotein (LDL), high-density lipoprotein (HDL) and cholesterol correlations to avoid interactions with possible drug effects (n=15). Adj., adjusted.
Figure 4. Phytoene dehydrogenase K10027 is enriched…
Figure 4. Phytoene dehydrogenase K10027 is enriched in the gut metagenome of healthy controls.
β-Carotene (P=0.05, Student’s t-test) but not lycopene (P=0.35, Student’s t-test) was enriched in serum of healthy controls. Red is patients (P), green controls (C). Boxes denote the interquartile range (IQR) between the first and third quartiles and the line within denotes the median; whiskers denote the lowest and highest values within 1.5 times IQR from the first and third quartiles, respectively. Circles denote data points beyond the whiskers.

References

    1. Bäckhed F., Ley R. E., Sonnenburg J. L., Peterson D. A., Gordon J. I. Host-bacterial mutualism in the human intestine. Science 307, 1915–1920 (2005).
    1. Cani P. D. et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 56, 1761–1772 (2007).
    1. Bäckhed F. et al. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl Acad. Sci. USA 101, 15718–15723 (2004).
    1. Ley R. E., Turnbaugh P. J., Klein S., Gordon J. I. Microbial ecology: human gut microbes associated with obesity. Nature 444, 1022–1023 (2006).
    1. Erridge C., Attina T., Spickett C. M., Webb D. J. A high-fat meal induces low-grade endotoxemia: evidence of a novel mechanism of postprandial inflammation. Am. J. Clin. Nutr. 86, 1286–1292 (2007).
    1. Schertzer J. D. et al. NOD1 activators link innate immunity to insulin resistance. Diabetes 60, 2206–2215 (2011).
    1. Qin J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
    1. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
    1. Turnbaugh P. J. et al. A core gut microbiome in obese and lean twins. Nature 457, 480–484 (2009).
    1. Greenblum S., Turnbaugh P. J., Borenstein E. Metagenomic systems biology of the human gut microbiome reveals topological shifts associated with obesity and inflammatory bowel disease. Proc. Natl Acad. Sci. USA 109, 594–599 (2012).
    1. Wang Z. et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472, 57–63 (2011).
    1. Koren O. et al. Human oral, gut, and plaque microbiota in patients with atherosclerosis. Proc. Natl Acad. Sci. USA 108, Suppl 14592–4598 (2011).
    1. Arumugam M. et al. Enterotypes of the human gut microbiome. Nature 473, 174–180 (2011).
    1. Tap J. et al. Towards the human intestinal microbiota phylogenetic core. Environ. Microbiol. 11, 2574–2584 (2009).
    1. Wu G. D. et al. Linking long-term dietary patterns with gut microbial enterotypes. Science 334, 105–8 (2011).
    1. Zhu W., Lomsadze A., Borodovsky M. Ab initio gene identification in metagenomic sequences. Nucleic Acids Res. 38, e132 (2010).
    1. Oliveira A. P., Patil K. R., Nielsen J. Architecture of transcriptional regulatory circuits is knitted over the topology of bio-molecular interaction networks. BMC Syst. Biol. 2, 17 (2008).
    1. Patil K. R., Nielsen J. Uncovering transcriptional regulation of metabolism by using metabolic network topology. Proc. Natl Acad. Sci. USA 102, 2685–2689 (2005).
    1. Maslowski K. M. et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461, 1282–1286 (2009).
    1. Hansson G. K. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352, 1685–1695 (2005).
    1. Kardinaal A. F. et al. Antioxidants in adipose tissue and risk of myocardial infarction: the EURAMIC Study. Lancet 342, 1379–1384 (1993).
    1. Kohlmeier L. et al. Lycopene and myocardial infarction risk in the EURAMIC study. Am. J. Epidemiol. 146, 618–626 (1997).
    1. Hennekens C. H. et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N. Engl. J. Med. 334, 1145–1149 (1996).
    1. Kritchevsky S. B. beta-Carotene, carotenoids and the prevention of coronary heart disease. J. Nutr. 129, 5–8 (1999).
    1. Rissanen T. H. et al. Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am. J. Clin. Nutr. 77, 133–138 (2003).
    1. Sesso H. D., Buring J. E., Norkus E. P., Gaziano J. M. Plasma lycopene, other carotenoids, and retinol and the risk of cardiovascular disease in women. Am. J. Clin. Nutr. 79, 47–53 (2004).
    1. Bermudez O. I., Ribaya-Mercado J. D., Talegawkar S. A., Tucker K. L. Hispanic and non-Hispanic white elders from Massachusetts have different patterns of carotenoid intake and plasma concentrations. J. Nutr. 135, 1496–1502 (2005).
    1. Khaneja R. et al. Carotenoids found in Bacillus. J. Appl. Microbiol. 108, 1889–1902 (2010).
    1. Perez-Fons L. et al. Identification and the developmental formation of carotenoid pigments in the yellow/orange Bacillus spore-formers. Biochim. Biophys. Acta 1811, 177–185 (2011).
    1. Fagerberg B. et al. Differences in lesion severity and cellular composition between in vivo assessed upstream and downstream sides of human symptomatic carotid atherosclerotic plaques. J. Vasc. Res. 47, 221–230 (2010).
    1. Christensen H., Boysen G. C-reactive protein and white blood cell count increases in the first 24 hours after acute stroke. Cerebrovasc. Dis. 18, 214–219 (2004).
    1. Fagerberg B., Kellis D., Bergstrom G., Behre C. J. Adiponectin in relation to insulin sensitivity and insulin secretion in the development of type 2 diabetes: a prospective study in 64-year-old women. J. Intern. Med. 269, 636–643 (2011).
    1. Schmidt C., Wikstrand J. High apoB/apoA-I ratio is associated with increased progression rate of carotid artery intima-media thickness in clinically healthy 58-year-old men: experiences from very long-term follow-up in the AIR study. Atherosclerosis 205, 284–289 (2009).
    1. Mathiesen E. B., Bonaa K. H., Joakimsen O. Echolucent plaques are associated with high risk of ischemic cerebrovascular events in carotid stenosis: the tromso study. Circulation 103, 2171–2175 (2001).
    1. Prahl U. et al. Percentage white: a new feature for ultrasound classification of plaque echogenicity in carotid artery atherosclerosis. Ultrasound Med. Biol. 36, 218–226 (2010).
    1. Salonen A. et al. Comparative analysis of fecal DNA extraction methods with phylogenetic microarray: effective recovery of bacterial and archaeal DNA using mechanical cell lysis. J. Microbiol. Methods 81, 127–134 (2010).
    1. Cox M. P., Peterson D. A., Biggs P. J. SolexaQA: At-a-glance quality assessment of Illumina second-generation sequencing data. BMC Bioinformatics 11, 485 (2010).
    1. Langmead B., Trapnell C., Pop M., Salzberg S. L. Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25 (2009).
    1. Zerbino D. R., Birney E. Velvet: algorithms for de novo short read assembly using de Bruijn graphs. Genome Res. 18, 821–829 (2008).
    1. Edgar R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
    1. Eddy S. R. Profile hidden Markov models. Bioinformatics 14, 755–763 (1998).
    1. Cantarel B. L. et al. The carbohydrate-active EnZymes database (CAZy): an expert resource for glycogenomics. Nucleic Acids Res. 37, D233–238 (2009).
    1. Edgar R. C. Search and clustering orders of magnitude faster than BLAST. Bioinformatics 26, 2460–2461 (2010).
    1. Benjamini Y., Hochberg Y. Controlling the false discovery rate—a practical and powerful approach to multiple testing. J. Roy. Stat. Soc. B Met. 57, 289–300 (1995).
    1. Dray S., Dufour A. B. The ade4 package: Implementing the duality diagram for ecologists. J. Stat. Softw. 22, 1–20 (2007).
    1. Sowell A. L., Huff D. L., Yeager P. R., Caudill S. P., Gunter E. W. Retinol, alpha-tocopherol, lutein/zeaxanthin, beta-cryptoxanthin, lycopene, alpha-carotene, trans-beta-carotene, and four retinyl esters in serum determined simultaneously by reversed-phase HPLC with multiwavelength detection. Clin. Chem. 40, 411–416 (1994).

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir